Cholangiocarcinoma in Wales – ITV News Report

#AMMF #VoicesofCholangiocarcinoma - Shaping the Future

#AMMF #VoicesofCholangiocarcinoma - Tamara’s Story

#AMMF #VoicesofCholangiocarcinoma - Liam’s Story

#AMMF #VoicesofCholangiocarcinoma - Tania’s Story

5. Session Five: Palliative Care Explained: Myths, Meaning and Reality

#AMMF #VoicesofCholangiocarcinoma - Louise’s Story

#AMMF #VoicesofCholangiocarcinoma - Kevin’s Story

#AMMF #VoicesofCholangiocarcinoma - Louise’s Story

#AMMF #VoicesofCholangiocarcinoma - Leah’s Story

#AMMF #VoicesofCholangiocarcinoma - Florence’s Story

Day 3: Conference highlights and closing remarks

Day 3: Question Time 15:10 - 15:25

Day 3: 'Fast Science' and Best Poster award presentations

Day 3: The Centrosome-Ciliary genes as a therapeutic target in bile duct cancer

Day 3: Immune Profiling of Cholangiocarcinoma and Evaluation of Human Precision-Cut Tumour Slices...

Day 3: Human Precision-Cut Tumour Slices (hPCTS) and Immune Co-Culture Systems to Assess and Enha...

Day 3: Defining Metabolic Zonation as a Determinant of Hepatocyte Plasticity

Day 3: Multiplexed detection of cell-free DNA, microRNA, and protein biomarkers to diagnose Chola...

Day 3: Question Time 14:15 - 14:25

Day 3: Introduction to Fast Science Session

Day 3: AI-CCA: Artificial Intelligence as a Biomarker for Intrahepatic Cholangiocarcinoma

Day 3: Question Time 12:30 - 12:45

Day 3: Interrogating tumour mediated immunosuppression in peri-hilar cholangiocarcinoma

Day 3: The role of IDH mutation in liver cell plasticity and intrahepatic cholangiocarcinoma

Day 3: Normal cholangiocyte containment of cholangiocarcinoma through metabolic and transcriptomi...

Day 3: AMMF and AstraZeneca in Conversation: Collaborating for Progress in Cholangiocarcinoma

Day 3: Introduction to Session

Day 3: Next generation liquid biopsy biomarkers for CCA

Day 3: "HistotripsyNon-invasive, Non-ionisation, Non-thermal Liver Surgery"

Day 3: ATTAINMENT Study

Day 3: Take a deep breath: How a breath test could revolutionise the early detection of liver cancer

Day 3: Introduction to session

Day 3: Patient Perspective

Day 3: Welcome

Day 2: Question Time 17:10 - 17:20

Day 2: Closing Comments - End of Day Two

Day 2: Update on the work of Precision BTC Network

Day 2: CCA in Spain

Day 2: Published Biomarker Work

Day 2: Screening and surgery for CCA:  The Thai Experience

Day 2: Co-chairs Introduction to international sessions

Day 2: Patient Perspective -"It's Difficult to sum up what I've gone through in a title"

Day 2: Question Time 15:05 - 15:15

Day 2: Update on SIRT

Day 2: Spotlight on CCA in Wales

Day 2:Adherence to best practice guidelines for the management of intrahepatic CCA: results from...

Day 2: Co-chair introduction to afternoon and first session

Day 2: Question Time 12:50-13:10

Day 2: Liver Transplantation in CCA

Day 2: Optimising the surgical management of CCA

Day 2: BSG Guidelines on the diagnosis and management of GBC

Day 2: The Aspirin Study

Day 2: Patient Perspective

Day 2: Question Time  10:45 - 11:00

Day 2: Radiotherapy in BTC

Day 2: Targeted therapies, immunotherapies, trial updates (ABC-10, SAFIR IMPACT)

Day 2: Molecular profiling across the UK

Day 2: CCA Epidemiology – new data

Day 2: Session co-chairs welcome